# US 2013/0157357 A1 · Lentiviral vectors for the preparation of immunotherapeutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157357 A1
- Document ID: US20130157357A1
- Status: Published application
- Kind: A1
- Application number: 13/711,898
- Filed: 2012-12-12
- Published: 2013-06-20
- Earliest claimed: 1999-10-11
- Assignees: Institut Pasteur; Centre National De La Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale
- Inventors: Pierre CHARNEAU; Hüseyin FIRAT; Véronique ZENNOU
- Web page: https://patentgrep.com/patent/US20130157357A1

## CPC

- C12N 15/867: Retroviral vectors
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- C07K 14/35: from Mycobacteriaceae (F)
- C12N 15/86: Viral vectors
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2840/203: having an IRES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to an immunogenic composition comprising a recombinant vector characterized in that it comprises a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cell-mediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

An isolated recombinant cell transduced by a replication-defective lentiviral vector comprising a transgene, a lentiviral cis-acting central initiation region (cPPT), and a lentiviral cis-acting termination region (CTS), such that a triplex DNA is formed during reverse transcription of the vector.

### Claim 37 (depends on 36)

The recombinant cell of claim 36, wherein the lentiviral cPPT and CTS regions are HIV-1 cPPT and CTS regions.

### Claim 38 (depends on 36)

The recombinant cell of claim 36, wherein the lentiviral cPPT and CTS regions are CAEV, EIAV, VISNA HIV, SIV or FIV cPPT and CTS regions.

### Claim 39 (depends on 36)

The recombinant cell of claim 36, wherein the lentiviral vector further comprises HIV-1 regulatory signals for reverse transcription and packaging.

### Claim 40 (depends on 37)

The recombinant cell of claim 37, wherein the lentiviral vector further comprises HIV-1 regulatory signals for reverse transcription and packaging.

### Claim 41 (depends on 36)

The recombinant cell of claim 36, wherein the cell is a non-dividing cell.

### Claim 42 (depends on 37)

The recombinant cell of claim 37, wherein the cell is a non-dividing cell.

### Claim 43 (depends on 38)

The recombinant cell of claim 38, wherein the cell is a non-dividing cell.

### Claim 44 (depends on 39)

The recombinant cell of claim 39, wherein the cell is a non-dividing cell.

### Claim 45 (depends on 40)

The recombinant cell of claim 40, wherein the cell is a non-dividing cell.

### Claim 46 (depends on 36)

The recombinant cell of claim 36, wherein the cell is an antigen presenting cell.

### Claim 47 (depends on 37)

The recombinant cell of claim 37, wherein the cell is an antigen presenting cell.

### Claim 48 (depends on 38)

The recombinant cell of claim 38, wherein the cell is an antigen presenting cell.

### Claim 49 (depends on 39)

The recombinant cell of claim 39, wherein the cell is an antigen presenting cell.

### Claim 50 (depends on 40)

The recombinant cell of claim 40, wherein the cell is an antigen presenting cell.

### Claim 51 (depends on 36)

The recombinant cell of claim 36, wherein the cell is a lung, brain, epithelial, astrocyte, mycroglia, oligodendrocyte, neuron, muscle, hepatic, dendritic, neuronal, bone marrow, macrophage, fibroblast, or hematopoietic cell.

### Claim 52 (depends on 37)

The recombinant cell of claim 37, wherein the cell is a lung, brain, epithelial, astrocyte, mycroglia, oligodendrocyte, neuron, muscle, hepatic, dendritic, neuronal, bone marrow, macrophage, fibroblast, or hematopoietic cell.

### Claim 53 (depends on 38)

The recombinant cell of claim 38, wherein the cell is a lung, brain, epithelial, astrocyte, mycroglia, oligodendrocyte, neuron, muscle, hepatic, dendritic, neuronal, bone marrow, macrophage, fibroblast, or hematopoietic cell.

### Claim 54 (depends on 39)

The recombinant cell of claim 39, wherein the cell is a lung, brain, epithelial, astrocyte, mycroglia, oligodendrocyte, neuron, muscle, hepatic, dendritic, neuronal, bone marrow, macrophage, fibroblast, or hematopoietic cell.

### Claim 55 (depends on 40)

The recombinant cell of claim 40, wherein the cell is a lung, brain, epithelial, astrocyte, mycroglia, oligodendrocyte, neuron, muscle, hepatic, dendritic, neuronal, bone marrow, macrophage, fibroblast, or hematopoietic cell.

### Claim 56 (depends on 36)

The recombinant cell of claim 36, wherein the cell is a tumor or cancer cell.

### Claim 57 (depends on 37)

The recombinant cell of claim 37, wherein the cell is a tumor or cancer cell.

### Claim 58 (depends on 38)

The recombinant cell of claim 38, wherein the cell is a tumor or cancer cell.

### Claim 59 (depends on 39)

The recombinant cell of claim 39, wherein the cell is a tumor or cancer cell.

### Claim 60 (depends on 40)

The recombinant cell of claim 40, wherein the cell is a tumor or cancer cell.
